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Abstract Longitudinal studies exploring sexuality, body image and health-related quality
of life (HRQoL) are lacking in patients treated with chemo- or chemoimmuno-therapy for
hematologic malignancies. The aim was to describe and explore changes in sexuality, body
image and HRQoL in patients treated for hematologic malignancies, from baseline until
6 months after treatment. Twenty patients above 45 years (median age 62) treated for
DLBCL, CLL or AML participated. Data were collected at baseline, 1- and 6-months after
treatment by means of three instruments: SAQ-S, BIS and EORTC QLQ-C30. The results
showed that patients’ sexuality was negatively affected 1 month after treatment, but after
6 months the patient reported scores had returned almost entirely to baseline scores. Body
image was slight negatively affected after 1 month and after 6 months, 50 % reported that
body image was not affected at all. Regarding HRQoL, patients reported gradually
improved scores during the study period. Regression analysis showed that changes in
sexuality and body image seemed to influence changes in HRQoL. This study has shown
changes in sexuality, body image and HRQoL over time in patients above age 45 treated
for hematologic malignancies. One month after treatment all three areas becomes nega-
tively affected, and thereafter the patients’ scores recovered to a great extent regarding
these issues within 6 months. Sexuality and body image seem to be important aspects of
HRQoL for these patients and need to be integrated in the cancer rehabilitation during and
after treatment.
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Background
In Sweden, about 1400 individuals (median age 70 years) are diagnosed with diffuse large
B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) or acute myeloid leu-
kemia (AML) every year [1]. Recent developments within the field of supportive care have
enabled the treatment of patients who previously were considered to be too fragile to
manage the expected side-effects [2]. Hence, the number of patients being treated and
surviving the diseases have increased during the last years. Cancer diagnosis and associ-
ated treatments often imply complex and long-lasting physical and psychosocial problems
for the individual [2, 3]. Therefore, there is an increasing need to focus on health related
quality of life (HRQoL) issues both during and after treatment. Research in patients treated
for various hematologic malignancies shows that HRQoL is most negatively affected at
diagnosis, during treatment [3–5] and at the initial period after treatment. Thereafter,
physical, psychological and emotional well-being gradually improves [3, 5]. However, the
knowledge is scarce regarding in what ways and for how long sexuality is affected in
patients treated for hematologic malignancies.
Sexuality in nursing research is described as a concept that includes physiological,
psychological, social and socio-cultural dimensions interacting in a complex manner
[6–10]. It is acknowledged that cancer diagnosis and associated treatments have an impact
on all these dimensions in a multifaceted way [9–12]. In spite of this, studies focusing
sexuality in non sex-specific cancer populations are lacking. The existing research focusing
on sexuality in patients with hematologic malignancies mostly concerns fertility [13] and/
or sexual function [14–18] in rather young patients, treated for Hodgkin lymphoma
[13–16], or patients who have undergone hematopoietic stem cells transplantation [17, 18].
These studies show that in general patients experience affected sexuality during treatment
and for a short period afterward. Furthermore, being female [10], older age [13, 19], in an
advanced state of illness, having poorer physical health and high degree of emotional
distress [19, 20], seem to be associated with a higher risk for affected sexuality such as
reduced sexual function [13–18], and decreased sexual desire [21]. In addition, a quali-
tative study has shown that both women and men diagnosed with DLBCL, CLL and AML,
experienced negative effects on their sexual relationships during and after treatment [22].
However, research in patients over the age of 45 treated for hematologic malignancies and
longitudinal studies that examine sexuality in relation to HRQoL in this special group of
patients is very rare [4].
Body image is one important aspect of both sexuality and HRQoL, which have been
studied to a very limited extent in patients with hematologic malignancies [22, 23].
However, Weber et al. [23] found that body image was negatively affected in newly
diagnosed patients and Olsson et al. [22] have shown that both women and men experience
changes in appearance leading to feelings of being sexually unattractive, decreased sexual
desire and avoidance of intimacy.
In summary, the issue of how sexuality is affected in patients with hematologic
malignancies is examined to a limited extent and previous studies have mainly focused on
fertility and function in rather young patients or in patients treated with hematopoietic stem
cells transplantation. However, patients with hematologic malignancies such as DLBCL,
CLL and AML are most often in their 50s or older and the majority is treated with chemo-
or chemoimmuno-therapy. Furthermore, longitudinal studies and studies that examine
sexuality from a multidimensional perspective, including sexual interest, sexual satisfac-
tion and sexual function in relation to HRQoL and body image in patients with
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hematologic malignancies are rare. Studies such as these are needed as these could give
important information to be used when developing adequate supportive care programs for
this special group of patients.
Aim
The aim was to describe and explore changes in sexuality, body image and HRQoL in
patients treated for hematologic malignancies, from baseline until 6 months after
treatment.
Methods
Study Design and Data Collection and Sample
This longitudinal study present data from three occasions for measurement: after the
second cycle of chemo- or chemoimmuno-therapy (Baseline), 1 month-(Follow-up 1) and
6 months after completion of treatment (Follow-up 2). Data was collected between June
2010 and January 2013 at seven units in four hospitals in central Sweden. Patients were
included consecutively. The study has a descriptive and explorative design. Inclusion
criteria were patients with one of the diagnoses DLBCL, AML or CLL and treated with
chemotherapy or chemoimmunotherapy (i.e. in this study a combination of chemotherapy
agents and monoclonal antibodies). An additional criterion used was that the patients
should be C45 year and able to read and write Swedish. Exclusion criteria were earlier
treatment for hematologic malignancies, relapsed disease or stem cells transplantation. The
Swedish Cancer Registry at the Regional Cancer Centre Uppsala-O¨rebro was used in order
to identify potential participants. Registered nurses responsible for carrying out patients’
treatment and care served as patient recruiting nurses. In connection with the second cycle
of treatment, the patient recruiting nurses gave verbal information about the study and
asked the patients verbally about participation. Written information about the aim and
design of the study, voluntariness and confidentiality was also given to the patients. When
patients agreed to participate, the patients’ demographic and medical characteristics were
collected by the recruiting nurses, and the researcher (CO) sent the first package of
questionnaires to the patient by ordinary mail. The second package (Follow-up 1) was sent
1 month after the treatment was completed and the third package (Follow-up 2) was sent
6 month after the treatment was completed. Up to two reminders were sent, 2 weeks apart.
Initially 99 patients were invited to participate and 46 of those agreed. However, 12 men
and two women never returned the questionnaires at baseline (mean age 67 years, range
52–78). Out of the 32 responding patients at baseline, 25 patients also responded at
‘Follow-up 1’, 1 month after the treatment was completed. Data for the 32 patients at
baseline and 25 patients at Follow-up 1 is presented in an earlier study [24]. At ‘Follow-up
2’, 6 month after treatment, 20 patients responded the questionnaires. One woman returned
the first follow-up nearly 6 month after treatment, this questionnaire was used as a ‘Fol-
low-up 2’ instead, which is shown in the flow chart of number of responding and non-
responding participants (Fig. 1).
The known reason for not participate in this longitudinal study was due to; patient
considered the content of the instrument as irrelevant at the present time of life (n = 4),
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comorbidity (n = 1), relapse of disease (n = 3) or death (n = 2). There were no statis-
tically significant differences regarding sex, age, civil status, level of education and
comorbidity between the responding and the non-responding group of patients at baseline,
Follow-up 1 and Follow-up 2.
Instrument
The Sexual Adjustment Questionnaire-Swedish version
The Sexual Adjustment Questionnaire (SAQ) is an instrument developed to measure
changes in sexuality (over time) in cancer patients, and has undergone validity and reli-
ability testing [25, 26]. The SAQ [19] was translated into Swedish (SAQ-S) by the research
team. The translation procedure is described in detail earlier [24] and additionally further
down in the paragraph Body Image Scale (BIS). Permission to translate and use the SAQ
was obtained from the author of the original instrument.
SAQ-S exists in four versions, one baseline and one follow-up, for men and women
respectively. The SAQ-S consists of 16 unisex items at baseline, of which fifteen had a
corresponding item in the follow-up version. One question is only in the baseline version
and two occurs only in the follow-up version. The baseline versions measure ‘how sex-
uality was experienced before diagnoses’ and the follow-up version measure ‘how sexu-
ality is experienced at present’. There are also sex-specific question, one ‘female’ and two
Patients responded to 
the questionnaires at 
Baseline (n=32)
Patients responded to 
the questionnaires at
Follow-up 2 (n=20) 
Patients responded to 
questionnaires at
Follow-up 1 (n=25)
Patients not responding to the 
3rd package of questionnaires 
(n=6)
Patients not responding to the 
2nd package of questionnaires 
(n=7)
Patients not responding to the 
1st package of questionnaires 
(n=14)
Patients agreed to 
participate 
(n=46)
Patients invited to 
participate 
(n=99)
One questionnaire returned 
after 18 weeks and considered 
as a Follow-up 2 (n=1)
Fig. 1 Flow chart for sample and drop-outs for the study
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‘male’. The response options represented a five-point Likert scale, except for one item with
a six-point scale. There was also a possibility to score ‘not applicable’. High scores
indicate more positive feelings or functioning in the item areas. To calculate a SAQ-S total
mean value, all unisex items mean value were added and divided by the number of item.
According to the constructor of SAQ, professor Wilmoth (personal contact, October 2,
2013) the items could be grouped into the three modified scales for men. On the bases of
the content, they were labeled as follows: sexual interest (six items), sexual function (five
items) and sexual satisfaction (five items). In the present study, the SAQ-S was modified to
be unisex, and thus was used for both men and women. Therefore, the two gender-specific
items were removed in the Sexual Function scale and the unisex item did/do you have
problems with your sexual ability was included. In the scale sexual satisfaction, the item
did/do you feel tense or frustrated after a sexual experience was previously removed from
the Swedish version due to cross-cultural aspect during the translation. Internal consistency
was calculated with Cronbach’s alpha coefficient [27], which was at the three occasion of
measurement, respectively: sexual interest, .75, .88, .87, sexual function was .86, .41, .84
and sexual satisfaction was .73, .86, .60.
Body Image Scale
The Body Image Scale (BIS) was developed for assessment of cancer patients’ perception
of their own body image and consist of 10 items which have undergone validity and
reliability testing [21]. Cronbach’s alpha has earlier shown good values .78–.92 [28, 29].
BIS was translated into Swedish by the research team. Permission to translate and use the
BIS was obtained from the author of the original instrument [28]. The translation procedure
was done according to recommended guidelines for cross-cultural adaption [30, 31]. Two
bilingual persons, one with knowledge of the subject, translated the instrument from
English into Swedish. Some issues were discussed with persons with specialist knowledge
of the subject, and the research team content- and cultural-validated the instrument.
Thereafter, a bilingual third translator blindly translated the Swedish version into English.
In this study we removed the items have you been feeling that the treatment has left your
body less whole and have you been dissatisfied with the appearance of your scar, since
these items were not applicable for our study group. A four point Likert like scale rep-
resented the item response options, ‘Not at all’, ‘A little’, ‘Quite a bit’ and ‘Very much’,
which score 1–4, respectively. The mean value of all items were added and divided by
eight in order to calculate a BIS total mean value. The BIS total score of all items in this
study could vary by 8–32, with a lower score representing a better body image. Internal
consistency was calculated with Cronbach’s alpha coefficient [27] which for BIS was .91 at
Follow-up 1, and .92 at Follow-up 2.
The European Organization for Research and Treatment of Cancer Quality of Life
Questionnaires
The European Organization for Research and Treatment of Cancer Quality of Life ques-
tionnaires (EORTC QLQ-C30, version 3) is an instrument for assessment of cancer
patients HRQoL which have undergone extensive validity and reliability testing [32, 33].
Cronbach’s alpha has earlier been considered acceptable for the multi-item scales ranged
.52–.89 [32]. EORTC QLQ-C30 consists of five functional scales: physically, mentally,
emotionally, socially and cognitively and three symptom scales: fatigue, nausea/vomiting,
and pain, five single symptoms items about shortness of breath, insomnia, loss of appetite,
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constipation, diarrhea, as well as one concerning Global Health status/QoL scale. The 30
item instrument also includes a single item about financial difficulties. All items cover
experiences ‘during the last week’. A four point Likert like scale represented the item
response options ‘Not at all’, ‘A little’, ‘Quite a bit’ and ‘Very much’. The two items in
Global Health status/QoL scale have a seven-point range from ‘Very poor’ to ‘Excellent’.
The scales and single-item measures from 0 to 100, where a higher functional scale score
represent a high level of functioning and a high score for global health status/QoL rep-
resent a high HRQoL. On the contrary a low score on one symptom scale represent a low
level of problems/symptoms [34]. Internal consistency was calculated with Cronbach’s
alpha coefficient [27], which for the multi-item scales ranged from .55 to .96 at Baseline,
from .48 to .93 at Follow-up 1, and from .31 to .95 at Follow-up 2.
Ethical Approval
The research was carried out in accordance with ethical principles and guidelines as
outlined in ‘Ethical guidelines for nursing research in the Nordic Countries’ [35], in line
with the ‘Declaration of Helsinki’ [36]. The study was approved by the Regional Ethical
Review Board in Uppsala (Dnr. 2010/065). Written informed consent was obtained when
the questionnaires were completed and sent back to the researcher. Permission to carry out
the study was given by the respective Head of departments from which the informants were
recruited.
Statistical Analysis
Descriptive statistics were used to describe patient data: frequencies, percent, mean,
median (MD) and standard deviation (SD). Fisher’s exact test and t test were used to
examine differences between the non-responding participants compared with the
responding participants at Baseline, Follow-up 1 and Follow-up 2. Mean values for the
study group was illustrated by using 95 % confidence intervals (CI) for the SAQ-S total,
Global Health status/QoL and for BIS. For the comparison with SAQ-S total the scores for
Global Health status/QoL was converted from 0–100 to 0–5. Wilcoxon signed-rank test
was used to examine differences between related groups, at ‘Baseline–Follow-up 1’ and at
‘Follow-up 1–Follow-up 2’.
The area under study is unexplored, therefore linear regression analyses [27] were
carried out to further explore how changes in differences for sexuality and body image
explained changes in differences for quality of life between the occasions for measurement.
The summarized individual mean values of the ‘changes in differences’ between the
occasions for measurement were calculated for each scale (diff 1 = difference between
Baseline and Follow up 1: and diff 2 = difference between Follow up 1 and Follow up 2).
Diff 1 and diff 2 was used as variables in the analysis. Dependent variable was the outcome
measures Global Health status/QoL Scale diff. The independent variables Sexual Interest
diff, Sexual Function diff, Sexual Satisfaction diff, Body Image Scale diff and Sex were
entered simultaneously. Three participants were excluded list-wise in the SAQ-S in the
regression analyses. All statistical tests were two-tailed, and P B .05 was considered
statistically significant [27]. All statistical analyses were performed using the Statistical
Package for Social Sciences (SPSS) version 20.0.
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Results
This study is based on 20 patients (13 men and 7 women) with a mean age of 62.5 years
(Md = 62.5, range 50–79 years), who remained in the study at 6 months after treatment.
The majority of the participants had a partner and education at the university level. The
predominant diagnosis was DLBCL, and most patients were treated with chemoim-
munotherapy (R-CHOP). Patient demographics and medical characteristics are shown in
Table 1. However, the number of individuals varied in the different analyzes depending on
the patients’ use of the response alternative ‘not applicable’ and a few internal drop-outs.
All of the patients included (n = 20) answered the SAQ-S and the EORTC QLQ-C30 at
























Living apart 2 (10)
Living alone 3 (15)
Widow/widower 1 (5)
Education level
Elementary school 6 (30)
Upper secondary school 3 (15)
University 10 (50)





On sick leave 2 (10)
Diagnosis
Diffuse large B cell lymphoma (DLBCL) 14 (70)
Chronic lymphocytic leukemia (CLL) 3 (15)
Acute myeloid leukemia (AML) 3 (15)
Chemimmunotherapy
R-CHOPa 13 (65)
Other treatment regimenb 7 (35)
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Baseline. At Follow-up 1, 19 patients answered the SAQ-S and 18 patients answered the
EORTC QLQ-C30 and the BIS. At Follow up 2, all of the 20 patients answered the three
instruments.
An overall description of changes during the study period based on total scores shows
that the patients reported negatively affected sexuality (SAQ-S) at 1 month after treatment,
compared to before treatment (Baseline: mean 3.49, CI 3.20–3.79, Follow-up 1: mean 2.78,
CI 2.27–3.29). Six months after the treatment patients’ reported scores had almost returned
to baseline (Follow-up 2: mean 3.35, CI 2.94–3.75). Regarding Global Health status/QoL a
gradually improvement was reported during the occasions for follow-up with the lowest
score reported at baseline (Baseline: mean 58.80, CI 50.10–67.50, Follow-up 1: mean
63.89, CI 55.48–72.30, and Follow-up 2: mean 76.85, CI 67.58–86.12). Body image was
slightly affected during the follow-up period with the greatest impact reported 1 month
after treatment (Follow-up 1: mean 12.22, CI 9.69–14.76, Follow-up 2: mean 11.00, CI
8.63–13.37). The changes related to SAQ-S and EORTC QLQ-C30 is illustrated in Fig. 2.
Changes Between Baseline and Follow-up 1 Regarding SAQ-S and EORTC
QLQ-C30
When comparing changes regarding sexuality (SAQ-S) on an item level most of the
patients reported lower scores on a majority of the items at Follow-up 1 compared to
Baseline. There was a statistically significant decrease in five of the unisex items scores.
Fig. 2 Mean values and confidence interval for SAQ-S total and Global Health status/QoL Scale, at
Baseline, Follow-up 1 and Follow-up 2 (n = 18)
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The patients reported decreased desire for sexual activity, frequencies of sexual activity,
and how often sexual activity was/is pleasurable. They also more often felt too tired for
sexual activity, and experienced worse problems getting sexually aroused/turned on
(Table 2).
Seven patients (37 %) out of nineteen reported ‘no importance’ of sexual activity,
compared to baseline values (15 %, n = 3/20). The proportion of patients who scored ‘no
problems’ with sexual ability decreased (baseline: 67 %: n = 12/18, Follow-up 1: 25 %,
n = 3/12) indicating increasing problems. Nine patients (47 %) out of nineteen reported
that they ‘had not yet’ resumed sexual activity 1 month after treatment and most patients
(60 %, n = 9/15) reported that undergoing cancer treatment had negatively changed the
patients’ sexual relationship to partner/partners.
When comparing changes in patients’ scores on an item and sub-scale level for the
EORTC QLQ-30, no statistically significant differences were found (Table 3).
Changes Between Follow-up 1 and Follow-up 2 Regarding SAQ-S, BIS
and EORTC QLQ-C30
When comparing changes regarding sexuality most patients reported higher scores at
Follow-up 2 compared to Follow-up 1. There was a statistically significant increase in two
of the unisex items: desire for sexual activity, as well as frequencies of sexual activity
(Table 2). No other statistically significant differences were found.
At Follow-up 2, most patients (90 %, n = 17/19) reported that sexual activity was of
importance in varying degree in their life at present, and the proportion of patients who
scored ‘no problems’ regarding problems with sexual ability had increased (56 %, n = 10/
18). Seventeen patients (85 %) out of 20 had resumed sexual activity or had ‘never
stopped’ having sexual activity, while still more than half of patients (53 %, n = 8/15)
reported that undergoing cancer treatment had changed the patients’ sexual relationship to
partner/partners.
Regarding body image, patients reported statistically significant positive changes for
two of the eight items: feeling self-conscious about their appearance and feeling of less
physically attractive as a result of your disease or treatment (Table 4). In addition, at
Follow-up 2: eight patients (44 %, n = 8/18) scored that Body image was ‘not at all’
affected (in all items).
When comparing changes on an item and sub-scale level for the EORTC QLQ-C30
most of the patients reported higher scores at Follow-up 2 compared to Follow-up 1. The
patients’ score for the scale Global Health status/QoL and in three of the five functional
scales: Physical Scale, Role Scale and Social Scale showed a statistically significant
increase. Regarding the three symptom scales and six single items, the patients reported
less severity of symptoms and the scores were statistically significantly lower for the
symptom item fatigue and dyspnea. No other differences were found (Table 3).
Influence of Sexuality and Body Image on Changes in HRQoL
In the regression analysis, between Baseline and Follow-up 1 (diff 1), the results showed
that changes in sexuality influenced changes in HRQoL. The Sexual Interest diff 1
explained changes in Global Health status/QoL diff 1 (B = 27.50, P = .009) (Table 5).
Based on these results a further linear regression analysis was carried out which showed
that Sexual Interest diff 1 for men explained 33.6 % of the changes for Global Health
status/QoL diff 1. The corresponding figure for women was 2.7 % (Fig. 3).
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n Mean (SD) n Mean (SD) n Mean (SD) P P
Sexual interest
B. In the 6 months before
you found out you had
cancer, how important
was sexual activity in
your life?
F. What is the importance
of sexual activity in
your life right now?
20 2.55 (.95) 19 2.21 (1.18) 19 2.68 (1.00) .146 .172




B. Did you desire sexual
activity?
F. Do you have desire for
sexual activity?
20 3.61 (.82) 19 2.79 (1.13) 20 3.35 (1.27) .005 .031








19 2.79 (1.03) 16 2.38 (1.41) 16 2.69 (1.30) .188 .188









20 3.00 (1.00) 15 2.47 (1.41) 14 2.86 (1.23) .230 .766
B. Was it important for
you to reach orgasm?
F. Is it important for you
to reach orgasm?
20 3.95 (1.05) 18 3.72 (1.23) 20 3.80 (1.20) .547 .500
Sexual function
B. Were you too tired for
sexual activity?
F. Do you feel too tired
for sexual activity?
20 3.65 (.88) 18 3.06 (1.21) 19 3.37 (1.07) .044 .371
B. Before finding out you




















n Mean (SD) n Mean (SD) n Mean (SD) P P
F. Do you have problems
getting sexually
aroused/turned on?
20 4.15 (1.14) 15 3.53 (1.46) 19 3.74 (1.33) .031 .906
B. Did you have problems
in reaching orgasm or
did you feel that you
came too soon?
F. Since your cancer
treatment, do you have
problems in reaching
orgasm or did you feel
that you ‘come’ too
soon?
20 3.80 (1.06) 11 4.27 (.79) 19 3.95 (1.13) .656 1.00
B. Did you experience
problems with your
sexual ability before
finding out you had
cancer?
F. Have you experienced
problems with your
sexual ability since your
cancer treatment?
18 4.44 (.86) 12 3.50 (1.24) 18 4.00 (1.24) .063 .133
Sexual satisfaction
B. How often was sexual
activity pleasurable?
F. How often is sexual
activity pleasurable for
you now?
20 4.20 (.89) 16 3.31 (1.54) 19 3.68 (1.16) .016 .234
B. How often did you
have sexual activity
(with or without a
partner)?
F. How often do you have
sexual activity (with or
without a partner)?
20 2.50 (.95) 19 1.32 (1.29) 20 2.00 (1.30) .004 .027
B. Before finding out you
had cancer, did you feel
satisfied following
sexual activity?
F. Do you feel satisfied
following sexual
activity?
20 4.30 (.93) 12 4.08 (.90) 15 4.20 (1.08) .500 .500
B. Were you satisfied with
the frequency of sexual
activity in your life?
F. Are you satisfied with
the frequency of sexual
activity in your life?
20 3.70 (.98) 18 3.11 (1.18) 19 3.16 (1.21) .074 .759
















n Mean (SD) n Mean (SD) n Mean (SD) P P
Items not included in a scale
F. How soon after your
last cancer treatment did
you resume sexual
activity (on your own or
with another person)?
(only follow up)
19 2.74 (1.79) 20 3.50 (1.47) .077
B. Did you feel any pain
or discomfort during
sexual activity?
F. Do you feel any pain or
discomfort during
sexual activity?
20 4.55 (.83) 11 4.45 (.93) 18 4.28 (1.13) 1.00 1.00








17 2.35 (.79) 15 2.13 (.83) 16 2.31 (.70) .688 .250






15 2.20 (.78) 15 2.33 (.72) 1.00
B. Could you achieve an
erection when sexually
aroused?
F. Can you achieve
erection when sexually
aroused? (male)
12 4.25 (.97) 10 3.90 (1.20) 12 4.17 (1.12) .630 .688
B. Did you feel that it
took you a long time to
achieve an erection?
F. Do you feel that it takes
you long time to
achieve an erection?
(male)
13 3.85 (1.28) 9 3.44(1.51) 12 4.00 (1.04) .810 .250
B. Did you experience
vaginal dryness during
sexual activity?
378 Sex Disabil (2016) 34:367–388
123
In the regression analysis, between Follow-up 1 and Follow-up 2 (diff 2), the results
showed that changes in sexuality and body image influenced changes in HRQoL (Table 5).
The BIS diff 2 explained changes in Global Health status/QoL diff 2 (B = -2.21,
P = .028). A further linear regression analysis showed that Body Image diff 2 for men
explained 54.6 % of the changes for global health status/QoL diff 2. The corresponding
figure for women was 3 % (Fig. 4).
Discussion
This study provided data on self-estimated changes regarding sexuality, body image and
HRQoL in 20 patient with hematologic malignancies treated with chemo- or chemoim-
muno-therapy, above 45 years, from baseline until 6 months after treatment. The main
results of this study showed that patients’ sexuality was negatively affected 1 month after
treatment compared to baseline, and that after 6 months the patient reported scores had
almost returned to baseline scores. Body image was slightly affected 1 month after
treatment, and after 6 months 50 % of the patients reported that body image was not
affected at all. Regarding HRQoL patients reported gradually improved scores during the
study period and after 6 months the scores were comparable with a general population.
Regression analysis showed that changes in sexuality and body image seemed to influence
changes in HRQoL for men. The results from this study are an important contribution to
the knowledge in this scarcely studied area, even though the sample size was small. This
study provides both clinical relevant data in an area of importance for cancer rehabilitation
and a direction to future research such as larger longitudinal studies in order to verify the
result.
Body image is an important aspect of both sexuality [22, 37] and HRQoL [37]. In our
study the patients reported that their body image was only slightly or not at all affected.
Contradicting results are reported by Olsson et al. [22] who in a qualitative interview study
found that patients treated for hematologic malignancies experienced an impact on their















n Mean (SD) n Mean (SD) n Mean (SD) P P




7 3.57 (1.40) 1 4.00 6 3.50 (1.52)
Bold values indicate P B .05
Responses range from 1 to 5 except for one item with a six point scale. Higher scores indicate more possible
feelings or function in these areas
The response alternative 0 was used when the question was not applicable, except for the item with a six
point scale
Wilcoxon signed rank test (exact sig. two-tailed) between baseline-Follow up 1, Follow up 1–Follow up 2
B Baseline, F Follow-up
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changed and unrecognized body was described as affecting the sexual relationship. Fur-
thermore, Fallbjo¨rk et al. [38] and Katz [39] conclude that satisfaction with one’s own
body and the appearance are important factors in order to function sexually. Hence, the
question about how to measure the impact of body image in an adequate way for this
special group of patients remains to be answered in larger studies. Thereto, studies
focusing supportive interventions related to body image and sexual relationships need to
include evaluation of best ways of assessment and monitoring.
In this study the patients reported that HRQoL was negatively affected already at
baseline. A probable reason could be that baseline data was collected at a point of time when
side effects such as troublesome tiredness, insomnia and appetite loss often are severe. This
must be taken into account when evaluating the findings. However, 1 month after treatment
patients reported an improved HRQoL even though not statistically significant. It is note-
worthy that non-statistically significant results could be of clinical importance [40]. Another
way to judge changes regarding side-effects, symptoms and HRQoL could be to estimate
clinical important differences [31]. Some researchers within the field of HRQoL argue that a














Mean (SD) Mean (SD) Mean (SD) P P
Global health
status/QoLa
60.00 (17.44) 63.89 (16.91) 75.42 (19.40) .194 .001
Functional scalesa
Physical 69.67 (18.16)c 68.89 (21.81) 80.35 (18.52) .561 \.001
Role 41.67 (29.37) 51.85 (34.25) 77.50 (28.24) .511 .001
Emotional 78.75 (19.21) 81.48 (15.00) 82.92 (17.41) .609 .505
Cognitive 80.83 (21.81) 86.11 (17.38) 84.17 (13.76) .270 .453
Social 59.17 (27.29) 60.19 (23.67) 86.67 (18.42) .965 \.001
Symptom scales/itemsb
Fatigue 55.44 (25.97) 45.68 (20.43) 31.11 (20.90) .406 .002
Nausea and
vomiting
15.00 (21.56) 5.56 (16.17) .83 (3.73) .219 .250
Pain 16.67 (18.73) 20.37 (24.63) 21.67 (27.09) .707 .999
Dyspnoea 33.33 (24.18) 38.89 (26.20) 18.33 (22.88) .307 .004
Insomnia 35.00 (38.20) 18.52 (26.13) 31.67 (29.57) .180 .234
Appetite loss 28.33 (27.09) 11.11 (22.87) 8.33 (18.34) .072 .500
Constipation 18.33 (33.29) 9.26 (19.15) 5.00 (16.31) .266 .500
Diarrhoea 15.00 (17.01) 7.41 (18.28) 6.67 (13.68) .289 1.00
Financial
difficulties
25.00 (33.98) 18.52 (30.73) 11.67 (19.57) .438 .188
Bold values indicate P B .05
Wilcoxon signed rank test (exact sig. two-tailed), between Baseline and Follow up 1, Follow up 1 and
Follow up 2
a Score range from 0 to 100, with a higher score representing a higher level of functioning
b Score range from 0 to 100, with a higher score representing a greater degree of symptoms
c Baseline (n = 19)
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difference between two occasions of measurement on a subscale C10-points reflects a
difference of clinical importance [40, 41]. By using the ‘10-point difference method’ in our
study, the functional scale Role and the symptom scales fatigue, nausea and vomiting,
insomnia and appetite loss, showed improvements of clinical importance 1 month after
treatment and after 6 months the HRQoL score was comparable to a general population
[42]. In summary, our findings seem to be in line with earlier studies with participants in
various ages showing that long-term cancer survivors regardless of age appear to recover
almost completely with respect to physical, psychological and emotional well-being [3, 5].







Mean (SD) Mean (SD) P
Have you been feeling self-conscious about your appearance? 1.61 (.85) 1.22 (.55) .031
Have you felt less physically attractive as a result of your disease
or treatment?
2.28 (1.13) 1.67 (.77) .039
Have you been dissatisfied with your appearance when dressed? 1.56 (.86) 1.28 (.58) .125
Have you been feeling less feminine/masculine as a result of your
disease or treatment?
1.39 (.70) 1.39 (.85) 1.00
Did you find it difficult to look at yourself naked? 1.28 (.75) 1.39 (.92) .75
Have you been feeling less sexually attractive as a result of your
disease or treatment?
1.67 (.91) 1.67 (.97) 1.00
Did you avoid people because of the way you felt about your
appearance?
1.06 (.24) 1.06 (.24) 1.00
Have you felt dissatisfied with your body? 1.39 (.78) 1.33 (.84) 1.00
Bold values indicate P B .05
Wilcoxon signed rank test (exact sig. two-tailed), between Follow up 1 and Follow up 2
Score range from 1 to 4, with a lower score representing a higher degree of body image
Table 5 Contribution of characteristic sex, SAQ-S dimensions diff and Body Image Scale diff on global
health status/QoLdiff between the occasions of measurement
Global Health status/QoL-diff 1 Global Health status/QoL-diff 2
B SE P B SE P
Characteristics Characteristics
Sex -1.705 9.62 .862 Sex -10.346 7.76 .210
SAQ-S-scales SAQ-S-scales
Sexual Interest diff 1 27.501 8.83 .009 Sexual Interest diff 2 -5.288 7.83 .513
Sexual Function diff 1 3.746 7.13 .609 Sexual Function diff 2 4.089 7.13 .578
Sexual Satisfaction diff 1 10.081 7.15 .184 Sexual Satisfaction diff 2 2.783 4.93 .584
Body Image-diff 2 -2.211 .88 .028
R2 .484 R2 .488
Adjusted R2 .312 Adjusted R2 .256
Bold values indicate P B .05
diff Differences in patients score between two occasions of measurement, diff 1 between Baseline and
Follow up 1, diff 2 between Follow up 1 and Follow up 2
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In this study patients reported lack of sexual interest and fatigue was scored as the most
distressing symptom. Although there is evidence regarding the impact of fatigue on
physical, psychological and cognitive functioning [43] and global quality of life [44], its
impact on sexuality in patients with hematologic malignancies is scarcely studied. The
only study found showed that thoughts about sex simply were ‘not on the agenda’ due to a
lack of physical and psychological strength [22]. This highlights the need to identify and
assess fatigue and other symptoms affecting sexuality and design appropriate supportive
interventions together with the patients and eventual partner.
The negative impact on patients’ sexual relationship due to cancer and its treatment
described in this study has earlier been shown in studies on patients with sex-specific
cancer [11, 45, 46]. In addition, in the case of existing relational problems before the
cancer diagnosis, the problems have been shown to often worsen in the context of a cancer
[45, 46]. Sexuality has in several studies been described as an unmet supportive care need
[16, 47–49]. Support to the couples regarding affected sexual relationship could be
assumed to be needed during the first 6 months after treatment when patients are resuming
life again [22]. However, the patients in our study reported quite low importance of
sexuality at all three occasions for measurement and similar findings has also been found in
a qualitative study where patients also described few sexual problems and limited needs of
support [22]. Sexuality is to a large extent seen as a private and sensitive topic by both
patients and nurses [22, 50]. Therefore, we stress that it is a challenge to identify patients
Fig. 3 Linear regression: ‘changes in differences’ in Global Health status/QoL and SAQ-S Sexual Interest
among men and women, between Baseline and Follow-up 1. Men R2 linear = .336, women R2
linear = .027
382 Sex Disabil (2016) 34:367–388
123
during treatment and cancer rehabilitation that ascribe sexuality importance and also want
support regarding sexuality issues in order to avoid violation of patients’ integrity. Fur-
thermore, the nursing education has to ensure that nurse student are trained in commu-
nication regarding sensitive and taboo issues such as sexuality. In addition, the health care
leaders’ needs to acknowledge this area as being an important issue for nurses.
Strengths and Limitations
Sexuality, especially in relation to body image and HRQoL, has rarely been studied in
patients suffering from hematologic malignancies treated with chemo- or chemoimmuno-
therapy. Therefore the results of this study are an important contribution to the body of
knowledge in this area, even though the generalizability is limited due to the small size of
the sample. The low response rates could be assumed to be due to the sensitive nature of
the foci of the research [25], or because patient being exhausted due to severe symptoms
and side effects of treatment [22].
Even if SAQ is not in total congruence with the WHO’s [51] definition of sexuality it
was found to be the most suitable instrument for measuring affected sexuality in patients
with hematologic malignancies. The other instruments found measuring affected sexuality
were either sex-specific or considered to be too detailed regarding sexual dysfunction
[52–54]. An instrument, which encompasses the physical, psychological, intellectual, and
Fig. 4 Linear regression: ‘changes in differences’ in Global Health status/QoL and Body Image Scale
among men and women, between Follow-up 1 and Follow-up 2. Men R2 linear = .546, women R2
linear = .03
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social aspects of sexuality, as outlined in the definition of sexuality by the WHO, would be
preferable and an instrument where perspectives such as closeness, intimacy, tenderness
and body image are included is warranted.
The inclusion of BIS, which assesses an individual’s feelings and attitudes to their body
function and appearance, was an attempt to get closer to the WHO definition of sexuality.
To our knowledge, BIS has not been used previously in studies about sexuality in patients
treated for hematologic malignancies. However, the suitability of the content of the items
in BIS for the study group needs to be discussed, as they mainly concern external
appearance. Questions related to the internal experience of the body [55], which could be
assumed to be of importance for patients treated for hematologic malignancies, are
missing. Furthermore, two items were removed as they were considered to be applicable
only to patients who have undergone surgery. The removed item, ‘have you been feeling
that the treatment has left your body less whole’, might have given us additional infor-
mation related to the internal experiences of affected body image.
A longitudinal design with repeated measurements was chosen in this study, in order to
describe and explore changes in sexuality, body image and HRQoL from baseline until
6 months after treatment. For ethical reasons, baseline data were collected with connection
to the second cycle of treatment, a time when side-effects often are severe. Therefore,
recall bias has to be taken into consideration when evaluating the results. However, the
questions in SAQ-S were designed as ‘how sexuality was experienced before diagnoses’
and can therefore be assumed to reflect the situation before diagnosis. Furthermore, since
HRQoL has been described as already affected at the time for diagnosis in this group of
patients due to symptoms of the disease, it is not possible to obtain a ‘true’ baseline
regarding HRQoL.
The opportunity to further explore individual changes over time for the group of patients
in this study is presented by the regression analysis, enabled by access to the modified SAQ
scales. The sample size can be considered small for a regression analysis compared with
the recommended ten cases of data for the predictor in the model [27] but the longitudinal
design resulted in over 50 measuring points (17 patients on three occasions). The intention
was not to create a model; rather the regression analyses were used to explore how
sexuality and body image influenced HRQoL for the specific group of patients. These
results cannot be generalized, but have interesting information which needs to be further
studied in a larger sample.
Conclusion and Implication for Practice
This longitudinal study has shown changes in sexuality, body image and HRQoL over time
in patients above 45 years of age who were treated for hematologic malignancies. Sexu-
ality and HRQoL became negatively affected, and body image was slight negatively
affected after 1 month. The patients recovered to a great extent regarding all three areas
within a period of 6 months. One notable finding, even though this study was small, was
that sexuality and body image seemed to influence HRQoL for men at 1 and at 6 months.
Hence, this study highlights the necessity of considering issues related to sexuality and
body image in the supportive care of patients with hematologic malignancies. This might
be most important during the first 6 months after treatment when patients adjust to the life
as cancer survivors.
Assessment of problems and needs together with timely interventions such as infor-
mation and support is valuable for patients both during and after treatment. This also
applies for sensitive and taboo issues such as sexuality when preparing and adjusting to the
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life as cancer survivors. In the cancer rehabilitation team, the nurses, who are present
during the entire trajectory of care, have a key role working with holistic individual nursing
care aiming to promote well-being and as high quality of life as possible for the patients.
However, when supporting the patients, it is important for nurses to timely recognize the
diversity and complexity of the patients’ problems, including their unmet needs, in order to
give adequate support. Therefore, the care should be provided within the framework of
patient-centered care and organized in a way that implies continuity in the nurse-patient
relationship. When needed, the nurse also initiates intervention from other professions of
the rehabilitation team.
Further Research
Longitudinal multicenter studies focusing how chemo- and chemoimmuno-therapy regi-
mens affect patients’ sexuality, body image and HRQoL, enabling larger samples and
follow-up throughout the rehabilitation period are needed for developing evidence based
interventions. A larger sample is also needed in order to enable the evaluation and
development of the SAQ-S and BIS for the use in studies with patient treated for hema-
tologic malignancies. In addition, more knowledge is needed in order to understand how
sexuality, body image and HRQoL relate and impact on each other.
Thereto, in order to identify the adequate way of practice, intervention studies focusing
supportive care during treatment and the period of rehabilitation are needed from the
perspectives of both patients and personnel. It would also be valuable to study the issue
from the perspective of health care providers which could integrate issues related to health
economy. Furthermore, in order to prevent a situation where cancer patients’ supportive
care needs including sexuality is studied only from an outside perspective, members of
patients associations ought to be included in the research team when planning study design
and evaluation.
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